Kyverna reports durable 1-yr SPS and gMG data; BLA on track Q4 2026

Kyverna Therapeutics, Inc.

KYSA-8 SPS (n=26): median T25FW improvement 49% at 12 mo; 92% off chronic immunotherapies; no high-grade CRS/ICANS/IEC-HS.
KYSA-6 gMG (n=7): 100% achieved clinically meaningful MG-ADL/QMG improvement at 24 wks; 57% maintained MSE; 86% off immunosuppressants.
Rolling BLA for miv-cel in SPS on track for Q4 2026 completion; gMG Phase 3 enrollment expected mid-2027.
Data to be presented at MS Toronto (Oct 21-23, 2026) and AANEM (Sept 29, 2026).
Safety profile consistent: no high-grade CRS/ICANS and no IEC-HS across both trials through 1-yr follow-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.